M. Cinar, A. Dinc, and I. Simsek, Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study, Rheumatol Int, vol.30, pp.331-371, 2010.

B. Amor, M. Dougados, and M. Mijiyawa, Criteria of the classification of spondylarthropathies, Rev Rhum Mal Osteoartic, vol.57, pp.85-94, 1990.

R. S. Heijde-d-van-der and R. Landewé, update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Annals of the Rheumatic Diseases, 2016.

A. Moltó, S. Paternotte, and P. Claudepierre, Effectiveness of tumor necrosis factor ? blockers in early axial spondyloarthritis: data from the DESIR cohort, Arthritis & Rheumatology, vol.66, pp.1734-1778, 2014.

S. Ottaviani, Y. Allanore, and F. Tubach, Body mass index influences the response to infliximab in ankylosing spondylitis, Arthritis Res Ther, vol.14, p.115, 2012.
DOI : 10.1186/ar3841

URL : https://hal.archives-ouvertes.fr/inserm-00704843

E. Gremese, A. Carletto, and M. Padovan, Obesity and reduction of the response rate to anti-tumor necrosis factor ? in rheumatoid arthritis: an approach to a personalized medicine, Arthritis Care Res (Hoboken), vol.65, pp.94-100, 2013.

J. Rosas, F. Llinares-tello, and J. M. Senabre-gallego, Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis, Clin Exp Rheumatol, vol.35, pp.145-153, 2017.

A. Ciurea, A. Scherer, and U. Weber, Impaired response to treatment with tumour necrosis factor ? inhibitors in smokers with axial spondyloarthritis, Ann Rheum Dis, vol.75, pp.532-541, 2016.
DOI : 10.1136/annrheumdis-2013-205133

B. Glintborg, P. Højgaard, L. Hetland, and M. , Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry, Rheumatology (Oxford), vol.55, pp.659-68, 2016.

F. Yahya, K. Gaffney, and L. Hamilton, Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort, Rheumatology (Oxford), vol.57, pp.619-643, 2018.

M. Rudwaleit, P. Claudepierre, and P. Wordsworth, Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis, J Rheumatol, vol.36, pp.801-809, 2009.

B. Glintborg, M. Ostergaard, and N. S. Krogh, Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry, Ann Rheum Dis, vol.69, pp.2002-2010, 2010.

S. Arends, E. Brouwer, and E. Van-der-veer, Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study, Arthritis Res Ther, vol.13, p.94, 2011.

J. Sieper, D. Van-der-heijde, and M. Dougados, Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebocontrolled trial (ABILITY-1), Ann Rheum Dis, vol.72, pp.815-837, 2013.

X. Baraliakos, A. S. Koenig, and H. Jones, Predictors of Clinical Remission under Antitumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials, J Rheumatol, vol.42, pp.1418-1444, 2015.

L. E. Kristensen, J. A. Karlsson, and M. Englund, Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register, Arthritis Care Res (Hoboken), vol.62, pp.1362-1371, 2010.

E. Gremese, S. Bernardi, and S. Bonazza, Body weight, gender and response to TNF-? blockers in axial spondyloarthritis, Rheumatology (Oxford), vol.53, pp.875-81, 2014.

M. Lorenzin, A. Ortolan, and P. Frallonardo, Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab, BMC Musculoskelet Disord, vol.16, p.166, 2015.

E. Lubrano, F. M. Perrotta, and M. Manara, The Sex Influence on Response to Tumor Necrosis Factor-? Inhibitors and Remission in Axial Spondyloarthritis, J Rheumatol, vol.45, pp.195-201, 2018.

J. C. Davis, D. Van-der-heijde, and M. Dougados, Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept, J Rheumatol, vol.32, pp.1751-1755, 2005.

P. Lord, T. M. Farragher, and M. Lunt, Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for, Rheumatology Biologics Register. Rheumatology (Oxford), vol.49, pp.563-70, 2010.

M. Rudwaleit, S. Schwarzlose, and E. S. Hilgert, MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis, Ann Rheum Dis, vol.67, pp.1276-81, 2008.

L. Cantarini, M. Fabbroni, and R. Talarico, Effectiveness of Adalimumab in Nonradiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort, Medicine (Baltimore), vol.94, p.1170, 2015.

Z. Lin, Z. Liao, and J. Huang, Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients, Biomed Res Int, p.876040, 2015.

A. Ciurea, A. Scherer, and P. Exer, Tumor necrosis factor ? inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort, Arthritis Rheum, vol.65, pp.3096-106, 2013.

M. Luc, L. Gossec, and . Ruyssen-witrand, C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis, J Rheumatol, vol.34, pp.2078-81, 2007.

A. Calin, J. Porta, and J. F. Fries, Clinical history as a screening test for ankylosing spondylitis, JAMA, vol.237, pp.2613-2617, 1977.

M. Rudwaleit, A. Metter, and J. Listing, Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria, Arthritis Rheum, vol.54, pp.569-78, 2006.

M. Dougados, M. A. Agostino, and J. Benessiano, The DESIR cohort: a 10-year followup of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients, Joint Bone Spine, vol.78, pp.598-603, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00730858

M. Dougados, P. Simon, and J. Braun, ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis, Ann Rheum Dis, vol.70, pp.249-51, 2011.

P. Machado, R. Landewé, and E. Lie, Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

, Ann Rheum Dis, vol.70, pp.47-53, 2011.

S. Van-der-linden, H. A. Valkenburg, and A. Cats, Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria, Arthritis Rheum, vol.27, pp.361-369, 1984.

M. Rudwaleit, A. G. Jurik, and K. Hermann, Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group, Ann Rheum Dis, vol.68, pp.1520-1527, 2009.

C. López-medina, M. Dougados, and E. Collantes-estévez, Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis, Rheumatology (Oxford), vol.57, pp.880-90, 2018.

A. Moltó, S. Paternotte, and D. Comet, Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study, Arthritis Care Res (Hoboken), vol.65, pp.1472-81, 2013.

, Age, années, moyenne ± déviation standard (DS)

, Homme

, Durée de maladie, années, moyenne ± DS

, HLA-B27 présent, n (%)

O. Sacroiliitis,

, SpA axiale selon les critères ASAS, oui, n (%)

, Tabagisme actif, oui, n (%)

±. Crp and . Ds,

, Score ASAS NSAID les six derniers mois, moyenne ± DS